ERBB2 and breast cancer: Nanotechnology based drug formulation approved by the FDA include: Trastuzumab (ADC, antibody-drug conjugate targeting HER2 in HER2 positive BC), Abraxane (nab-paclitaxel, albumin bound nanoparticle bound to paclitaxel), Onivyde (irinotecan liposome injection), and more recently Onpattro (patisiran; first RNAi drug) [38,207,208,209].